Alendronate
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Postmenopausal osteoporosis — treatment | Postmenopausal women | Monotherapy | FDA Approved |
| Postmenopausal osteoporosis — prevention | Postmenopausal women | Monotherapy | FDA Approved |
| Increase bone mass in men with osteoporosis | Men with osteoporosis | Monotherapy | FDA Approved |
| Glucocorticoid-induced osteoporosis | Men and women on glucocorticoids ≥7.5 mg prednisone-equivalent daily with low bone mineral density | Monotherapy | FDA Approved |
| Paget’s disease of bone | Men and women with Paget’s disease who have alkaline phosphatase ≥2× upper limit of normal, are symptomatic, or are at risk for future complications | Monotherapy | FDA Approved |
The current FDA labelling notes that the optimal duration of use for osteoporosis has not been determined and that drug discontinuation should be considered after 3 to 5 years of use in patients at low fracture risk. Alendronate remains a first-line oral agent for postmenopausal osteoporosis and is endorsed by AACE/ACE 2020 and Endocrine Society 2019 guidelines for patients at high but not very-high fracture risk, with selection often driven by cost, generic availability, and the long-term outcome data from the Fracture Intervention Trial program.
Cancer treatment-induced bone loss (aromatase inhibitor or androgen-deprivation therapy) — used to attenuate BMD decline; evidence quality: moderate for BMD endpoints. Denosumab and zoledronic acid have stronger fracture-outcome data and are preferred in oncology guidelines.
Osteogenesis imperfecta in children — sometimes used by pediatric subspecialists. Evidence quality: low. The single FDA-reviewed pediatric study of 139 children with severe OI showed an increase in lumbar spine BMD Z-score but did not reduce fracture risk and had a markedly higher rate of vomiting (29.4% vs 10% placebo). IV pamidronate or zoledronic acid are more commonly used.
Fibrous dysplasia of bone — used to reduce bone pain and turnover markers; evidence quality: very low (small case series, no randomized data specifically for alendronate).
Hypercalcemia of malignancy — oral bisphosphonates are not appropriate for this indication because of poor and variable absorption; IV zoledronic acid or pamidronate are standard of care.
Dosing
All dosing organized by clinical scenario per the FDA prescribing information. Doses below assume normal renal function (CrCl ≥35 mL/min). Administration technique is critical to safety and efficacy; see the counselling section for full instructions.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Postmenopausal osteoporosis — treatment | 70 mg PO once weekly | 70 mg once weekly | 70 mg/week | Weekly dosing preferred for adherence and tolerability Daily alternative: 10 mg PO once daily |
| Postmenopausal osteoporosis — prevention | 35 mg PO once weekly | 35 mg once weekly | 35 mg/week | For women at risk but without established osteoporosis Daily alternative: 5 mg PO once daily |
| Increase bone mass in men with osteoporosis | 70 mg PO once weekly | 70 mg once weekly | 70 mg/week | Increases lumbar spine and femoral neck BMD Daily alternative: 10 mg PO once daily |
| Glucocorticoid-induced osteoporosis — most patients | 5 mg PO once daily | 5 mg once daily | 10 mg/day | Indicated at glucocorticoid doses ≥7.5 mg prednisone-equivalent daily in patients with low BMD |
| Glucocorticoid-induced osteoporosis — postmenopausal women not on estrogen | 10 mg PO once daily | 10 mg once daily | 10 mg/day | Higher dose due to greater baseline bone loss |
| Paget’s disease of bone | 40 mg PO once daily | 40 mg once daily × 6 months | 40 mg/day | Re-treatment may be considered after a 6-month post-treatment interval if alkaline phosphatase rises or symptoms recur Ensure adequate calcium and vitamin D before initiation |
Renal Dose Adjustment
| Renal Function | Recommendation | Notes |
|---|---|---|
| CrCl 35–60 mL/min | Standard dose | No dosage adjustment required per FDA PI |
| CrCl <35 mL/min | Not recommended | Lack of clinical experience in this population; consider denosumab or non-pharmacologic approaches in consultation with bone-disease specialist |
Special Populations
- Hepatic impairment: No dosage adjustment required (alendronate is not metabolized and is not excreted in bile).
- Older adults (≥65 years): No dosage adjustment required. The Fracture Intervention Trial included 71% of participants aged ≥65 and 17% aged ≥75 with no overall efficacy or safety differences observed; reassess swallowing ability and ability to remain upright in frail patients.
- Pediatrics: Not indicated. Safety and efficacy were not established in the FDA-reviewed pediatric osteogenesis imperfecta study.
- Long-term therapy and drug holiday: The FDA labelling recommends reassessment for drug discontinuation after 3 to 5 years of use in patients at low fracture risk. The ASBMR Task Force recommends reassessment after 5 years of oral bisphosphonate therapy and supports up to 10 years of continuous therapy in those at high residual fracture risk.
Mean oral bioavailability is approximately 0.64% in women and 0.59% in men under fasted conditions. Bioavailability falls by approximately 40% when the dose is taken 0.5 to 1 hour before breakfast (compared with 2 hours before), and by approximately 60% when taken with coffee or orange juice. Bioavailability is essentially zero when alendronate is taken with or up to 2 hours after a meal. The tablet must be taken on first waking with at least 6 to 8 oz of plain water (the oral solution must be followed by at least 2 oz of water), with the patient remaining upright and fasting for at least 30 minutes. Failure to follow this routine is the single most common cause of perceived treatment failure.
Pharmacology
Mechanism of Action
Alendronate is a nitrogen-containing bisphosphonate that binds with high affinity to hydroxyapatite at sites of active bone remodeling. When osteoclasts resorb mineralized matrix containing the drug, alendronate is internalized and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This blocks prenylation of small GTPases (Ras, Rho, Rac) required for osteoclast cytoskeletal organization, ruffled border formation, and survival, ultimately reducing osteoclast activity and triggering apoptosis.
The net effect is a marked reduction in bone resorption. Because resorption and formation are coupled in the remodeling cycle, bone formation is also eventually reduced, but the decoupling during early treatment allows for net positive bone balance, increases in bone mineral density at the lumbar spine and hip, and reductions in fracture risk. Alendronate has no direct effect on osteoblasts, parathyroid hormone, or calcium-sensing receptors.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~0.64% (women) / ~0.59% (men) under fasted conditions; reduced by ~40% if taken 0.5–1 h before breakfast and by ~60% with coffee or orange juice; near zero with food | Strict fasting administration with plain water is mandatory; bioavailability is the primary modifiable determinant of efficacy |
| Distribution | Steady-state Vd ≥28 L exclusive of bone; ~78% plasma protein binding; rapidly partitions to bone or excreted unchanged | Tissue distribution outside bone is minimal; predictable dosing across body habitus |
| Metabolism | Not metabolized in animals or humans; no CYP450 involvement | No clinically significant pharmacokinetic drug-drug interactions via hepatic metabolism |
| Elimination | ~50% of an IV dose excreted unchanged in urine within 72 h; renal clearance ~71 mL/min; bone-bound fraction released slowly with terminal half-life >10 years | Avoid in CrCl <35 mL/min; pharmacologic effect persists for months to years after discontinuation, supporting drug-holiday strategy |
Side Effects
Adverse-event profile is dominated by upper gastrointestinal symptoms and musculoskeletal complaints. Incidence rates below derive from the FDA prescribing information Table 1: the US/Multinational pivotal studies of alendronate 10 mg daily in postmenopausal women (n=196 alendronate vs n=397 placebo). Rates from the larger Fracture Intervention Trial cohort (n=3236 alendronate at 5–10 mg/day vs n=3223 placebo) were substantially lower across all categories.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| No drug-related adverse reaction reached ≥10% incidence in the pivotal placebo-controlled adult osteoporosis trials reported in the FDA prescribing information. Pediatric osteogenesis imperfecta patients (off-label) had a 29.4% rate of vomiting versus 10% on placebo. | ||
| Adverse Effect | Incidence (vs placebo) | Clinical Note |
|---|---|---|
| Abdominal pain | 6.6% vs 4.8% | Re-check administration technique; rule out reflux disease before discontinuing |
| Musculoskeletal pain (bone, muscle, or joint) | 4.1% vs 2.5% | Usually mild and self-limited; severe debilitating pain warrants discontinuation per FDA Warnings |
| Nausea | 3.6% vs 4.0% | Numerically similar to placebo; reassess fasting interval and water volume |
| Dyspepsia | 3.6% vs 3.5% | Often reflects technique error or pre-existing GERD; usually responsive to short PPI course |
| Constipation | 3.1% vs 1.8% | Address with hydration and fibre; usually does not require discontinuation |
| Diarrhea | 3.1% vs 1.8% | Mild and self-limiting in most cases |
| Headache | 2.6% vs 1.5% | Usually transient; rarely requires intervention |
| Flatulence | 2.6% vs 0.5% | Rarely treatment-limiting |
| Acid regurgitation | 2.0% vs 4.3% | Numerically lower than placebo in this study; verify upright posture for ≥30 min after dose if reported |
| Esophageal ulcer | 1.5% vs 0.0% | Discontinue and refer for endoscopy if persistent dysphagia, odynophagia, or retrosternal pain develops |
| Vomiting | 1.0% vs 1.5% | Numerically similar to placebo |
| Dysphagia | 1.0% vs 0.0% | Reassess esophageal motility; consider holding therapy |
| Abdominal distention | 1.0% vs 0.8% | Numerically similar to placebo; rarely treatment-limiting |
| Transient acute-phase reaction (myalgia, malaise, asthenia, fever) | Frequency not established (post-marketing) | Typically with first dose; resolves in 1–3 days; oral agents have a much milder profile than IV bisphosphonates |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe esophagitis, esophageal erosion, ulcer, stricture, or perforation | Rare (post-marketing) | Days to months | Discontinue; urgent upper endoscopy if dysphagia, odynophagia, retrosternal pain, or new/worsening heartburn |
| Osteonecrosis of the jaw (ONJ) | Rare (post-marketing); generally associated with tooth extraction or local infection with delayed healing | Months to years; risk may increase with cumulative bisphosphonate exposure | Pre-treatment dental exam in high-risk patients; refer to oral-maxillofacial surgeon if exposed bone develops |
| Atypical low-energy or low-trauma femoral shaft fracture (subtrochanteric or diaphyseal); atypical fractures of other bones also reported | Rare; risk increases with bisphosphonate duration; may be bilateral | Often after >3 years of therapy; prodromal dull aching thigh pain weeks to months before complete fracture | Discontinue; image affected and contralateral femur; orthopedic referral; reassess risk/benefit and consider drug interruption |
| Severe and occasionally incapacitating bone, joint, or muscle pain | Rare (post-marketing); rates were similar to placebo in randomized trials | One day to several months after starting therapy | Discontinue; most patients have relief after stopping; do not rechallenge given recurrence risk |
| Symptomatic hypocalcemia | Rare; generally with predisposing conditions | Days to weeks | Verify and correct calcium and vitamin D before initiation; risk highest in CKD, vitamin D deficiency, or hypoparathyroidism |
| Hypersensitivity reactions (urticaria, angioedema) | Rare (post-marketing) | Hours to weeks | Discontinue immediately; emergency care for airway involvement |
| Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); rash with photosensitivity, alopecia | Very rare (post-marketing) | Days to weeks | Discontinue immediately; emergency dermatology referral for any mucocutaneous reaction |
| Uveitis, scleritis, episcleritis | Rare (post-marketing) | Days to months | Discontinue and refer to ophthalmology for any new ocular pain, redness, or visual change |
| Acute asthma exacerbation | Rare (post-marketing) | Variable | Standard asthma exacerbation management; reassess therapy continuation |
| Other post-marketing reports: gastric/duodenal ulcers, oropharyngeal ulceration, joint swelling, peripheral edema, dizziness, vertigo, cholesteatoma of the external auditory canal | Frequency not established | Variable | Evaluate and manage per usual practice; consider drug discontinuation if causality suspected |
| Population / Regimen | Discontinuation Rate | Context |
|---|---|---|
| Prevention of postmenopausal osteoporosis (5 mg/day) | 7.5% vs 5.7% placebo | Pooled 2- to 3-year prevention studies (n=642 vs n=648) |
| Paget’s disease (40 mg/day for 6 months) | 6.4% vs 2.4% placebo | Higher dose increases upper-GI tolerability burden (17.7% vs 10.2% upper-GI events vs placebo) |
| Glucocorticoid-induced osteoporosis (5 or 10 mg/day) | Generally similar to placebo | 1-year studies showed comparable overall safety and tolerability profiles |
| Pediatric osteogenesis imperfecta (off-label) | Not the principal endpoint | Vomiting occurred in 29.4% vs 10% placebo over 24 months; no fracture-risk reduction shown |
Most upper-GI complaints reflect administration error rather than a true drug effect. Before discontinuing, confirm: (1) the tablet is taken on first waking with at least 6 to 8 oz of plain water (or oral solution followed by ≥2 oz water); (2) the patient remains upright for at least 30 minutes; (3) no food, beverage other than plain water, or other medication is consumed during the fasting interval; and (4) there is no untreated GERD. Discontinue and seek medical attention immediately for dysphagia, odynophagia, retrosternal pain, or new/worsening heartburn. If symptoms persist despite correct technique, consider transition to an IV bisphosphonate (zoledronic acid) or denosumab.
Drug Interactions
Alendronate is not metabolized by CYP450 enzymes and has no clinically significant pharmacokinetic interactions through hepatic pathways. The dominant interaction mechanism is reduced gastrointestinal absorption from chelation with polyvalent cations or food. The FDA prescribing information specifically lists calcium supplements, antacids, oral medications containing multivalent cations, aspirin, and NSAIDs in the Drug Interactions section.
Some clinical references describe additional theoretical interactions with proton pump inhibitors (possible attenuation of fracture-protective effect; observational data are inconsistent), aminoglycosides (additive hypocalcemia risk), and loop diuretics (increased renal calcium loss). These are not specifically addressed in the FDA prescribing information drug-interactions section and require individualized clinical judgment rather than systematic avoidance.
Monitoring
Monitoring focuses on confirming therapeutic response, ensuring safe long-term exposure, and recognizing the predictable adverse events of bisphosphonate therapy. Recommendations below combine FDA labelling guidance with current AACE/ACE 2020 and ASBMR Task Force 2016 consensus.
-
Bone mineral density (DEXA)
Baseline, then every 1–2 years per guideline practice
Routine Lumbar spine and total hip / femoral neck T-scores. Stable or improving BMD on therapy is expected. The FDA PI specifically recommends baseline BMD at initiation of glucocorticoid-induced osteoporosis therapy with repeat after 6 to 12 months of combined therapy. -
Serum calcium
Baseline; recheck if symptomatic or with clinical change
Routine FDA labelling requires hypocalcemia to be corrected before initiation. Asymptomatic decreases of approximately 2% in serum calcium and 4–6% in serum phosphate occurred in the first month of FOSAMAX 10 mg therapy in pivotal studies. Monitor more closely in CKD, vitamin D deficiency, hypoparathyroidism, or Paget’s disease. -
25-OH vitamin D
Baseline; periodic reassessment per individual risk
Routine FDA PI advises that patients at increased risk for vitamin D insufficiency (over age 70, nursing home-bound, or chronically ill) may need supplementation. Patients with GI malabsorption may require higher doses and 25-OH vitamin D measurement. -
Serum creatinine / eGFR
Baseline; reassess with intercurrent illness or new nephrotoxic exposure
Routine FDA PI: alendronate is not recommended in CrCl <35 mL/min. No dosage adjustment in CrCl 35–60 mL/min. -
Bone turnover markers (CTX, P1NP)
Optional; baseline and 3–6 months after initiation if used
Trigger-based Not part of FDA-labelled monitoring but used in some practices to confirm pharmacologic effect and adherence early. A meaningful drop from baseline supports adequate response. -
Dental examination
Pre-treatment in high-risk patients; routine dental care during therapy
Trigger-based FDA PI lists invasive dental procedures, cancer diagnosis, concomitant chemotherapy/corticosteroids/anti-angiogenic therapy, poor oral hygiene, and pre-existing dental disease as ONJ risk factors. Pre-treatment dental assessment is advisable in these populations. Routine dental cleanings and simple restorations do not require interruption of alendronate. -
Femoral fracture screening
If new thigh, hip, or groin pain
Trigger-based Per the FDA Warnings and Precautions, any patient with a history of bisphosphonate exposure presenting with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Image bilateral femurs; assess for atypical features (transverse fracture line, lateral cortical thickening). Risk/benefit of continuing therapy should be reassessed and interruption considered. -
Fracture risk reassessment for drug holiday
After 3 to 5 years of continuous oral therapy
Routine FDA labelling: patients at low fracture risk should be considered for drug discontinuation after 3 to 5 years; reassess fracture risk periodically thereafter. ASBMR Task Force suggests reassessment after 5 years of oral therapy with up to 10 years of continuous use possible in those at high residual fracture risk. -
Adherence and administration technique
Every visit
Routine Verbal check at each follow-up: timing relative to food, water volume, upright posture, fasting interval. Real-world persistence with oral bisphosphonates is widely reported as suboptimal; structured counselling improves outcomes.
Contraindications & Cautions
Absolute Contraindications (per FDA prescribing information)
- Abnormalities of the esophagus that delay esophageal emptying — including stricture or achalasia.
- Inability to stand or sit upright for at least 30 minutes.
- Hypocalcemia — must be corrected before initiation.
- Hypersensitivity to any component of the product — including reported urticaria and angioedema.
- Oral solution formulation in patients at increased risk of aspiration.
Use Not Recommended (Specialist Input Advised)
- Severe renal impairment (CrCl <35 mL/min) — not recommended per FDA PI due to lack of clinical experience.
- Active upper GI disease — Barrett’s esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers — caution per FDA Warnings; defer until controlled or use alternative agent.
- Recent or planned invasive dental procedure in patients with additional ONJ risk factors (current or prior IV bisphosphonates, glucocorticoids, anti-angiogenic therapy, head and neck radiation, cancer diagnosis); defer initiation if feasible.
- Pregnancy or planned pregnancy — discontinue when pregnancy is recognized per FDA PI; bisphosphonates persist in bone and may pose theoretical fetal risk if conception occurs after therapy.
- History of atypical femoral fracture — strong relative contraindication; alternative agents preferred (denosumab, teriparatide).
Use with Caution
- Concurrent NSAIDs, aspirin (especially analgesic doses), or systemic glucocorticoids — additive GI risk and (with glucocorticoids) atypical femoral fracture risk noted in FDA labelling.
- Older adults with frailty, dementia, or aspiration risk — assess capacity to follow administration instructions; the oral solution is contraindicated when aspiration risk is elevated.
- Long-term therapy (>3 to 5 years) — reassess need at this interval per FDA labelling.
- Patients with poor dentition or active oral infection — address with dental team before or during therapy.
- Patients on Binosto effervescent on a sodium-restricted diet — Binosto contains sodium as a buffering agent.
The FDA issued a Drug Safety Communication on October 13, 2010, requiring a class-wide Warning regarding atypical low-energy or low-trauma fractures of the femoral shaft (subtrochanteric and diaphyseal) in patients on bisphosphonates approved for osteoporosis. The Warnings and Precautions section was updated again in February 2026 to clarify that atypical fractures of bones other than the femur have also been reported, that they may be bilateral, and that they can occur in osteoporotic patients who have not been treated with bisphosphonates. Concomitant glucocorticoid use may also induce these fractures.
Prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture, was reported by many patients. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated, and interruption of therapy should be considered. Osteonecrosis of the jaw and severe musculoskeletal pain are also recognized class-wide warnings; routine dental care should be maintained during therapy.
Patient Counselling
Purpose of Therapy
Explain that alendronate strengthens bone over months to years by reducing the rate at which old bone is removed. The medication does not reverse osteoporosis overnight; the goal is to prevent fractures, particularly of the spine and hip. Improvement in bone density typically takes 12 to 24 months to demonstrate on DEXA scanning, and many patients will not feel any difference day-to-day, which is normal. Adherence to weekly or daily dosing for years, combined with adequate dietary calcium and vitamin D, is what produces the protective effect.
How to Take
Per the FDA prescribing information, alendronate must be taken on first waking, before any food, drink, or other medication. Tablets must be swallowed whole with at least 6 to 8 oz (180–240 mL) of plain water — never coffee, tea, mineral water, juice, or milk. The oral solution must be followed by at least 2 oz of water. After swallowing the tablet whole (do not chew, crush, or suck), the patient must remain fully upright (sitting or standing) for at least 30 minutes and must continue fasting until the 30-minute interval has passed. Calcium supplements, antacids, vitamins with minerals, and any other oral medication must wait until after the 30-minute interval. Alendronate must not be taken at bedtime or before arising for the day. For weekly dosing, choose a fixed day. If a weekly dose is missed, take one dose the morning after remembering and resume the original schedule the following week — never take two doses on the same day.
Sources
- U.S. Food and Drug Administration / Organon LLC. FOSAMAX (alendronate sodium) tablets — full prescribing information. Revised February 2026. Available via DailyMed: dailymed.nlm.nih.gov Primary source for FDA-approved indications, dosing, contraindications, drug interactions, and the adult adverse-reaction tables (Table 1 incidence figures) cited throughout this monograph.
- U.S. Food and Drug Administration / Organon LLC. FOSAMAX PLUS D (alendronate sodium / cholecalciferol) tablets — full prescribing information. Available at: accessdata.fda.gov Reference for the alendronate / vitamin D combination product, including additional vitamin-D supplementation guidance.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. October 13, 2010. fda.gov Establishes the class-wide labelling for atypical femoral fractures and informs the duration-of-therapy reassessment recommendation; further updated in February 2026.
- Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333(22):1437–1443. doi.org/10.1056/NEJM199511303332201 US/Multinational pivotal trial that generated the adult adverse-reaction Table 1 incidence rates incorporated into the FDA prescribing information.
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535–1541. doi.org/10.1016/S0140-6736(96)07088-2 Fracture Intervention Trial vertebral-fracture cohort — foundational evidence for fracture-risk reduction with alendronate in women with prior vertebral fracture.
- Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: the Fracture Intervention Trial. JAMA. 1998;280(24):2077–2082. doi.org/10.1001/jama.280.24.2077 FIT clinical-fracture cohort in women with low BMD but no prior vertebral fracture; informs use in primary fracture prevention.
- Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX). JAMA. 2006;296(24):2927–2938. doi.org/10.1001/jama.296.24.2927 Foundational evidence for the bisphosphonate drug-holiday concept and the 5-year reassessment standard.
- Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–610. doi.org/10.1056/NEJM200008313430902 Primary RCT supporting the male osteoporosis indication.
- Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292–299. doi.org/10.1056/NEJM199807303390502 Pivotal trial supporting the glucocorticoid-induced osteoporosis indication.
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists / American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2020 update. Endocr Pract. 2020;26(Suppl 1):1–46. Executive summary: doi.org/10.4158/GL-2020-0524 Provides risk-stratified treatment selection for postmenopausal osteoporosis, including positioning of oral bisphosphonates as first-line therapy in non-very-high-risk patients.
- Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi.org/10.1210/jc.2019-00221 Endocrine Society guidance on initial therapy choice and duration; complements the AACE/ACE recommendations.
- Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. doi.org/10.1002/art.40137 Source for the GIO risk-stratified therapy approach used alongside the FDA-labelled dosing.
- Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16–35. doi.org/10.1002/jbmr.2708 ASBMR consensus on long-term therapy duration, drug holidays, and reassessment criteria.
- Shoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020;105(3):587–594. doi.org/10.1210/clinem/dgaa048 2020 update incorporating romosozumab and refining sequential-therapy recommendations relevant to alendronate positioning.
- Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19(6):733–759. doi.org/10.1007/s00198-007-0540-8 Comprehensive review of nitrogen-containing bisphosphonate pharmacology, including farnesyl pyrophosphate synthase inhibition.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. doi.org/10.1002/jbmr.2405 International consensus on ONJ definition, risk factors, and dental management.
- Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999;36(5):315–328. doi.org/10.2165/00003088-199936050-00002 Source for bioavailability, distribution, and renal-elimination data summarized in the ADME table.
- Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85. doi.org/10.1016/8756-3282(95)00445-9 Foundational pharmacokinetic review of the bisphosphonate class, covering bone uptake and slow release supporting the rationale for drug-holiday strategies.